placebo-controlled trial to report virologic outcomes of HC±AZ therapy in patients with asymptomatic or mild laboratory-confirmed Covid-19
doi: 10
The aim of this study was to evaluate the efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ) - PMC Journal List Elsevier - PMC COVID-19 Collection PMC9851717 As a library, NLM provides access to scientific literature
gov: NCT04308668) Setting: Internet-based trial across the United States and NIAID A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19)
14 - 17 Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial Lancet Reg Health Am
Participants will be randomised to receive hydroxychloroquine or placebo in a 1:1 ratio, in addition to standard of care (SoC) maintenance therapy with prednisolone and/or stable doses of azathioprine, methotrexate, mycophenolate, co-trimoxazole or maintenance therapy We did a randomised placebo-controlled trial to evaluate the safety and clinical efficacy of leflunomide and hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome
now report in the Journal the results of a randomized trial testing hydroxychloroquine as postexposure prophylaxis for Covid-19
A third trial randomized, placebo-controlled trial by Omrani et al
Full adherence to the trial intervention differed according to trial group, with 75
Other trials have reported either a mono-drug intervention versus placebo or higher doses of hydroxychloroquine plus azithromycin versus one of these drugs
(ClinicalTrials
3 percent, respectively
(Randomized trial of penicillamine [Pe] vs hydroxychloroquine [HCQ] vs placebo in 122 children with juvenile rheumatoid arthritis found minimal efficacy of HCQ; "marked" elevations in ALT occurred in 10% on PE, 18% on HCQ and 7% on placebo, all resolving without dose modification and perhaps due to concurrent use of aspirin or nonsteroidal This is a prospective, randomised 1:1 placebo-controlled, double-blind, and French multicentre trial of phase III (with two parallel-groups [HCQ 400 mg or placebo])
13 To our knowledge, the combination of leflunomide and hydroxychloroquine The ORCHID trial is a patient-level, parallel-group, blinded, randomized clinical trial evaluating the superiority of hydroxychloroquine compared with placebo
This trial was limited by case definition (PCR confirmed or clinically compatible) and a lack of uniform hydroxychloroquine yields little or no difference to risk of all-cause death (RR 1
In this randomized control double-blind clinical trial, asymptomatic We conducted a randomized, double-blind, placebo-controlled trial to evaluate postexposure prophylaxis with hydroxychloroquine after exposure to Covid-19
A total of 116 women (75 pregnant and 41 post‐partum) were enrolled from May 2020 to June 2021
No differences were observed in COVID‐19 progression, adverse Wright, J
Fourteen blinded, placebo-controlled RCTs were included in this meta-analysis
N Engl J Med 2020;383: 517-525
Methods: Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020
Therefore, it is useful to conduct this first meta-analysis pooling of all data on its adverse reactions to better understand its safety compared to placebo
Hydroxychloroquine increased qT interval, D-dimer, and trended towards an increased length of stay
We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure
This trial—Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among Inpatients With Symptomatic Disease (ORCHID)—was conducted to test the hypothesis that, compared with
This trial aims to explore Hydroxychloroquine as a treatment for patients with AAV
This document is the Statistical Analysis Plan for the ORCHID Trial and accompanies version 4 of the ORCHID protocol (dated June 4, 2020)
4%) patients required
showed HCQ with or without AZ was not associated with a difference in proportion of participants with viral clearance at day 6 Randomized double-blind placebo-controlled two-arm multicentre clinical trial to evaluate the safety and efficacy of HCQ to prevent and/or minimize SARS-CoV-2 infection during pregnancy
Author Footnotes
6% of those in the placebo group (336 of In each of these trials, participants were randomized to receive placebo or hydroxychloroquine
Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of healthcare workers with ongoing exposure to persons with SARS-CoV-2, including those working in emergency departments, intensive care units, COVID-19 hospital wards, and first responders
e
Written informed consent was
the placebo group); the score also did not The answer: 49 people in the hydroxychloroquine group and 58 people in the placebo group
Background: Synovitis is believed to play a role in producing symptoms in persons with hand osteoarthritis, but data on slow-acting anti-inflammatory treatments are sparse
The flexible platform trial design was intended to allow for additional agents to be added and tested with standardized operating procedures outlined in a single overarching protocol called a master protocol
effects, hydroxychloroquine was not clinically effective in a doubleblind, randomised, placebocontrolled trial